Literature DB >> 8710805

Short communication: selective placental transport of maternal IgG to the fetus.

P J Williams1, P D Arkwright, P Rudd, I G Scragg, C J Edge, M R Wormald, T W Rademacher.   

Abstract

During pregnancy there is a dramatic reduction in the serum levels of agalactosyl IgG (G0IgG) in both normal women and those with rheumatoid arthritis. In order to determine if a similar reduction in G0IgG were apparent in fetal serum, a comparison of the galactose content of IgG from nine paired samples of umbilical vein or fetal blood and peripheral maternal serum, at gestational ages ranging from 16-41 weeks was performed. The full-term maternal IgG samples were highly galactosylated, so confirming previous observations of reduced G0IgG levels during pregnancy. In addition every paired sample of fetal IgG had a higher level of galactosylation than the corresponding maternal IgG. Therefore, during pregnancy there is both a reduced biosynthesis of the G0IgG glycoform by the mother, and a restriction of its transport across the placenta. The ratio of estimated G0IgG in fetal and maternal serum was found to be related to changes in IgG transport, and in particular the active transport of IgG1 across the placenta during gestation. Our data suggest that the placental IgG transport mechanism is either carbohydrate independent by discriminating for IgG1, or is carbohydrate dependent selecting for highly galactosylated IgG glycoforms. This study emphasizes the need for further investigations on the biological function of G0IgG in normal physiological states, in addition to disease states, such as juvenile and adult rheumatoid arthritis, where elevated G0IgG levels correlate with disease activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8710805     DOI: 10.1016/0143-4004(95)90018-7

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  15 in total

1.  Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.

Authors:  Caitlin Milligan; Barbra A Richardson; Grace John-Stewart; Ruth Nduati; Julie Overbaugh
Journal:  Cell Host Microbe       Date:  2015-04-08       Impact factor: 21.023

2.  The history of IgG glycosylation and where we are now.

Authors:  Brian A Cobb
Journal:  Glycobiology       Date:  2020-03-20       Impact factor: 4.313

3.  Agalactosyl IgG and materno-fetal transmission of autoimmune neonatal lupus.

Authors:  C Pilkington; P V Taylor; E Silverman; D A Isenberg; A M Costello; G A Rook
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

4.  Immunoglobulin G Glycosylation Changes in Aging and Other Inflammatory Conditions.

Authors:  Fabio Dall'Olio; Nadia Malagolini
Journal:  Exp Suppl       Date:  2021

Review 5.  Estrogen-Driven Changes in Immunoglobulin G Fc Glycosylation.

Authors:  Kaitlyn A Lagattuta; Peter A Nigrovic
Journal:  Exp Suppl       Date:  2021

6.  HIV-Associated Alterations of the Biophysical Features of Maternal Antibodies Correlate With Their Reduced Transfer Across the Placenta.

Authors:  Sean A Taylor; Shilpee Sharma; Christopher A L Remmel; Beth Holder; Christine E Jones; Arnaud Marchant; Margaret E Ackerman
Journal:  J Infect Dis       Date:  2022-10-17       Impact factor: 7.759

Review 7.  Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

Authors:  Yusuke Mimura; Radka Saldova; Yuka Mimura-Kimura; Pauline M Rudd; Roy Jefferis
Journal:  Exp Suppl       Date:  2021

8.  The Impact of IgG transplacental transfer on early life immunity.

Authors:  Genevieve G Fouda; David R Martinez; Geeta K Swamy; Sallie R Permar
Journal:  Immunohorizons       Date:  2018-01-01

9.  Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G.

Authors:  Helga K Einarsdottir; Maurice H J Selman; Rick Kapur; Sicco Scherjon; Carolien A M Koeleman; André M Deelder; C Ellen van der Schoot; Gestur Vidarsson; Manfred Wuhrer
Journal:  Glycoconj J       Date:  2012-05-10       Impact factor: 2.916

10.  MALDI-TOF-MS reveals differential N-linked plasma- and IgG-glycosylation profiles between mothers and their newborns.

Authors:  Bas C Jansen; Albert Bondt; Karli R Reiding; Sicco A Scherjon; Gestur Vidarsson; Manfred Wuhrer
Journal:  Sci Rep       Date:  2016-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.